医学
钆酸
放射科
肝细胞癌
阶段(地层学)
临床终点
磁共振成像
介绍
治疗
前瞻性队列研究
机构审查委员会
临床试验
协议(科学)
结直肠癌
知情同意
癌症
不利影响
外科
病历
作者
H Park,D Lee,Won Chang,Hae Young Kim,D E Kim,Won-Mook Choi,Sung Won Chung,Jonggi Choi,D Lee,Ju Hyun Shim,Han Chu Lee,Young‐Suk Lim,Seon‐Ok Kim,Amit G Singal,S Y Kim,So Yeon Kim,So Yeon Kim
出处
期刊:BMJ Open
[BMJ]
日期:2026-04-01
卷期号:16 (4): e116809-e116809
标识
DOI:10.1136/bmjopen-2026-116809
摘要
INTRODUCTION: Hepatocellular carcinoma (HCC) recurs in most patients after curative treatment. Late recurrence (>2 years after curative treatment) typically indicates de novo tumours in the residual liver. Although contrast-enhanced computed tomography (CECT) and MRI are widely used for post-treatment follow-up, they each have limitations including radiation exposure, high cost and limited access. The abbreviated MRI using gadoxetic acid versus multiphasic CECT for detection of late recurrent HCC after curative treatment (AMRICT) trial aims to compare gadoxetic acid-enhanced abbreviated MRI using hepatobiliary phase imaging (HBP-AMRI) and multiphasic CECT for detecting late recurrent HCC after curative treatment. METHODS AND ANALYSIS: This prospective multicentre intra-individual comparison trial will enrol 455 participants who have undergone surgical resection or local ablation for HCC and remained recurrence-free for over 2 years. Each participant will undergo two imaging sessions at 6±2 month intervals, using both HBP-AMRI and multiphasic CECT. The primary endpoint is the detection rate of all-stage HCC. The secondary endpoints include the false referral rate of all-stage HCC and detection and false referral rates of Barcelona Clinic Liver Cancer stage 0-A HCC and of stage 0 HCC. Structured imaging protocols and quality assessments will be implemented for both modalities. ETHICS AND DISSEMINATION: This study was approved by the Institutional Review Boards of the three participating institutions (approval number: 2023-1630 (Asan Medical Center), H-2407-146-1556 (Seoul National University Hospital) and B-2410-929-401 (Seoul National University Bundang Hospital)) and registered at ClinicalTrials.gov (NCT06537193). Findings will be disseminated through peer-reviewed journals, scientific meetings, public forums and guideline updates. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT06537193. Participant enrolment began on 12 December 2024, and is ongoing.
科研通智能强力驱动
Strongly Powered by AbleSci AI